These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29029390)

  • 1. Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies.
    Florenzano F; Veronica C; Ciasca G; Ciotti MT; Pittaluga A; Olivero G; Feligioni M; Iannuzzi F; Latina V; Maria Sciacca MF; Sinopoli A; Milardi D; Pappalardo G; Marco S; Papi M; Atlante A; Bobba A; Borreca A; Calissano P; Amadoro G
    Oncotarget; 2017 Sep; 8(39):64745-64778. PubMed ID: 29029390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy.
    Borreca A; Latina V; Corsetti V; Middei S; Piccinin S; Della Valle F; Bussani R; Ammassari-Teule M; Nisticò R; Calissano P; Amadoro G
    Mol Neurobiol; 2018 Oct; 55(10):8124-8153. PubMed ID: 29508283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons.
    Amadoro G; Corsetti V; Florenzano F; Atlante A; Ciotti MT; Mongiardi MP; Bussani R; Nicolin V; Nori SL; Campanella M; Calissano P
    Neurobiol Dis; 2014 Feb; 62():489-507. PubMed ID: 24411077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
    Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
    J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.
    Sokolow S; Henkins KM; Bilousova T; Gonzalez B; Vinters HV; Miller CA; Cornwell L; Poon WW; Gylys KH
    J Neurochem; 2015 May; 133(3):368-79. PubMed ID: 25393609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice.
    Schultz MK; Gentzel R; Usenovic M; Gretzula C; Ware C; Parmentier-Batteur S; Schachter JB; Zariwala HA
    Neurobiol Dis; 2018 Oct; 118():161-176. PubMed ID: 30049665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue of tau-induced synaptic transmission pathology by paclitaxel.
    Erez H; Shemesh OA; Spira ME
    Front Cell Neurosci; 2014; 8():34. PubMed ID: 24574970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal tau truncation in the pathogenesis of Alzheimer's disease (AD): Developing a novel diagnostic and therapeutic approach.
    Amadoro G; Latina V; Corsetti V; Calissano P
    Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165584. PubMed ID: 31676377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias.
    Amadoro G; Corsetti V; Sancesario GM; Lubrano A; Melchiorri G; Bernardini S; Calissano P; Sancesario G
    J Alzheimers Dis; 2014; 42(1):211-26. PubMed ID: 24851856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum neurotoxin A modulates the axonal release of pathological tau in hippocampal neurons.
    Panzi C; Surana S; De La-Rocque S; Moretto E; Lazo OM; Schiavo G
    Toxicon; 2023 Jun; 228():107110. PubMed ID: 37037273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau₄₅₋₂₃₀ transgenic mice.
    Lang AE; Riherd Methner DN; Ferreira A
    Neuroscience; 2014 Sep; 275():322-39. PubMed ID: 24952329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau
    Ondrejcak T; Klyubin I; Corbett GT; Fraser G; Hong W; Mably AJ; Gardener M; Hammersley J; Perkinton MS; Billinton A; Walsh DM; Rowan MJ
    J Neurosci; 2018 Dec; 38(50):10595-10606. PubMed ID: 30355631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular Vesicles Isolated from Familial Alzheimer's Disease Neuronal Cultures Induce Aberrant Tau Phosphorylation in the Wild-Type Mouse Brain.
    Aulston B; Liu Q; Mante M; Florio J; Rissman RA; Yuan SH
    J Alzheimers Dis; 2019; 72(2):575-585. PubMed ID: 31594233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for tau at the synapse in Alzheimer's disease pathogenesis.
    Pooler AM; Noble W; Hanger DP
    Neuropharmacology; 2014 Jan; 76 Pt A():1-8. PubMed ID: 24076336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration.
    Amadoro G; Corsetti V; Atlante A; Florenzano F; Capsoni S; Bussani R; Mercanti D; Calissano P
    Neurobiol Aging; 2012 Apr; 33(4):833.e1-25. PubMed ID: 21958963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal loss and inflammation preceding fibrillary tau pathology in a rat model with early human-like tauopathy.
    Emmerson JT; Malcolm JC; Do Carmo S; Nguyen P; Breuillaud L; Martinez-Trujillo JC; Cuello AC
    Neurobiol Dis; 2023 Oct; 187():106317. PubMed ID: 37802153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies.
    Comerota MM; Tumurbaatar B; Krishnan B; Kayed R; Taglialatela G
    Mol Neurobiol; 2019 May; 56(5):3341-3355. PubMed ID: 30120733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies.
    Meduri G; Guillemeau K; Daguinot C; Dounane O; Genet M; Ferrara L; Chambraud B; Baulieu EE; Giustiniani J
    J Alzheimers Dis; 2023; 94(1):313-331. PubMed ID: 37248902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta.
    Miyoshi E; Bilousova T; Melnik M; Fakhrutdinov D; Poon WW; Vinters HV; Miller CA; Corrada M; Kawas C; Bohannan R; Caraway C; Elias C; Maina KN; Campagna JJ; John V; Gylys KH
    Lab Invest; 2021 Dec; 101(12):1605-1617. PubMed ID: 34462532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.